Journal: Experimental and Therapeutic Medicine

Article Title: Diammonium glycyrrhizinate lipid ligand ameliorates lipopolysaccharide-induced acute lung injury by modulating vascular endothelial barrier function

doi: 10.3892/etm.2021.9734

Figure Lengend Snippet: Effect of DGLL on the regulation of tight junction protein expression in rat lung tissue after LPS treatment. (A) Representative immunofluorescence confocal images for Occludin expression in lung tissues in (a) Sham, (b) LPS, (c) DGLL 30 + LPS, (d) DGLL 60 + LPS and (e) DGLL 120 + LPS groups. Red, Occludin; green, vWF; blue, Hoeschst 33342 (nuclear). Scale bar, 5 µm. (B) Representative western blot image and quantitative analysis of (C) ZO-1, (D) occludin and (E) JAM-1 in rat lung tissue. All data are expressed as the mean ± SEM. * P<0.05 vs. Sham; # P<0.05 vs. LPS. DGLL, diammonium glycyrrhizinate lipid ligand; LPS, lipopolysaccharide; JAM-1, junction adhesion molecule-1; ZO-1, zonula occludens-1; vWF, von Willebrand factor.

Article Snippet: Following separation by 8% SDS-PAGE electrophoresis (100 mg protein for each group), the protein samples were transferred onto PVDF membranes for blocking by 5% non-fat milk at room temperature for 1 h. The following primary antibodies and concentrations were used: intercellular adhesion molecule (ICAM)-1 (1:1,000; Abcam; cat. no. ab206398), vascular endothelial (VE)-cadherin (1:500; Invitrogen; Thermo Fisher Scientific, Inc.; cat. no. 36-1900), zonula occludens (ZO)-1 (1:1,000; Invitrogen; Thermo Fisher Scientific, Inc.; cat. no. 40-2200), Occludin (1:500; Invitrogen; Thermo Fisher Scientific, Inc.; cat. no. 33-1500), junctional adhesion molecule (JAM)-1 (1:1,000; Santa Cruz Biotechnology, Inc.; cat. no. sc-53623) and GAPDH (1:5,000; Cell Signaling Technology, Inc.; cat. no. 2118).

Techniques: Expressing, Immunofluorescence, Western Blot